

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8209660

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SUZHOU ZANRONG PHARMA LIMITED	07/10/2023
RECEIVING PARTY DATA	
Name:	F. HOFFMANN-LA ROCHE AG
Street Address:	GRENZACHERSTRASSE 124, CH-4070
City:	BASEL
State/Country:	SWITZERLAND
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	17051176
Application Number:	18319509
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	18888868168
Email:	patent@junhe.com
Correspondent Name:	JUN HE LAW OFFICES P. C.
Address Line 1:	20380 TOWN CENTER LANE, SUITE 128
Address Line 4:	CUPERTINO, CALIFORNIA 95014
ATTORNEY DOCKET NUMBER:	072890-8001US
NAME OF SUBMITTER:	JAMES J. ZHU
SIGNATURE:	/James J. Zhu, Reg. No. 52,396/
DATE SIGNED:	10/06/2023
Total Attachments: 3	
source=1_Zion to FHLR Assignment notarized#page1.tif	
source=1_Zion to FHLR Assignment notarized#page2.tif	
source=1_Zion to FHLR Assignment notarized#page3.tif	

ASSIGNMENT AGREEMENT

Suzhou Zanrong Pharma Limited (苏州赞荣医药科技有限公司) ("ASSIGNOR") a corporation organized under and existing under and by virtue of the laws of the People's Republic of China, with company number 91320594MA1YUQL08E and with its registered office at 218 Xinghu Rd. Building A6, Room 404, Biomedical Industrial Park, Suzhou, Jiangsu Province, the People's Republic of China 215123,

acknowledges the transfer to

F. Hoffmann-La Roche AG ("ASSIGNEE") a corporation organized under and existing under and by virtue of the laws of Switzerland, and having its place of business at Grenzacherstrasse 124, CH-4070 Basel, Switzerland

for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, of all right, title, and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in, to, and deriving from the invention(s) disclosed in the patent applications set forth below and its possessions by operation of law, contract, or otherwise, and any patent(s) which may hereafter be granted therefor including any application(s) the claim benefit to any applications set forth below and any priority application(s) from which that any of the applications claims benefit; and any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof.

As far as the right, title, and interest of ASSIGNOR in, to, and deriving from the invention(s) disclosed in the patent applications set forth below may not have been transferred, for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby assigns, sells and transfers to ASSIGNEE, and to ASSIGNEE'S successors and assigns, all of ASSIGNOR'S right, including the right to claim priority, title and interest in, to, and deriving from the invention(s) described in the patent application(s) listed below, including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof, or other patent applications claiming the benefit of the filing date of any of the following patent applications:

Title	Country	Patent Application Number	Filing Date	Publication Number
QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS	PCT	PCT/CN2018/106098	18 Sep 2018	Unpublished
QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS	PCT	PCT/CN2019/091078	13 June 2019	Unpublished
QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS	PCT	PCT/CN2019/106233	17 Sep 2019	WO2020057511 A1
QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS	US	US 17/051176	17 Sep 2019	US 2021/0386742 A1
QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS	US	US 18/319,509	18 May 2023	Unpublished
QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS	EP	EP19862146A	17 Sep 2019	EP3853220A1/ EP3853220A4
QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS	CA	CA3099776A	17 Sep 2019	CA3099776A1
QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS	AU	AU2019341273A	17 Sep 2019	AU2019341273A1
抗腫瘍剤としてのキノゾリン誘導体	JP	JP2021514381A	17 Sep 2019	JP2022501338A
항종양제로서의 퀴나졸린 유도체	KR	KR20217003251A	17 Sep 2019	KR20210061329A
ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS	PCT	PCT/CN2020079097	13 Mar 2020	WO2021179274 A1
ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS	CA	CA3175102A	13 Mar 2020	CA3175102A1



Title	Country	Patent Application Number	Filing Date	Publication Number
ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS	AU	AU2020435503A	13 Mar 2020	AU2020435503A1
CRYSTALLINE FORMS OF QUINAZOLINE DERIVATIVES, PREPARATION, COMPOSITION AND USE THEREOF	PCT	PCT/CN2021/125018	20 Oct 2021	Unpublished
CRYSTALLINE FORMS OF QUINAZOLINE DERIVATIVES, PREPARATION, COMPOSITION AND USE THEREOF	PCT	PCT/CN2022/126169	19 Oct 2022	WO2023066296 A1

ASSIGNEE, by virtue of this Assignment, shall have the right to file and own patent applications that claim priority to and are based in whole or in part on the patent applications set forth above and to own patent(s) granted therefor. Accordingly, ASSIGNOR hereby authorizes and requests to issue patents or other forms of industrial property protection on applications as aforesaid to ASSIGNEE, its successors and assigns in accordance with the terms of this assignment.

This agreement shall be governed and construed in accordance with substantive laws of Switzerland, with the exclusion of the Vienna Convention on the International Sale of Goods dated April 11, 1980. The competent courts of Basel City, Switzerland shall have exclusive jurisdiction.

ASSIGNOR

Suzhou Zanrong Pharma Limited



Shanghai, 2023-07-10
Place, Date

Signatures

ASSIGNEE


F. Hoffmann-La Roche AG

Basel, 18. JULI 2023
Place, Date

Signatures

Dr. Frank Sauer
Vice Director

Beat Rauber
Vice Director



Legalization

The undersigned Notary Public of the Canton of Basel-Stadt (Switzerland), Dr. Christoph Nertz, herewith legalizes the overleaf signature, affixed before him, of

F. Hoffmann-La Roche AG., a stock company with legal domicile in Basel (Switzerland), rendered by Mister Beat Rauber, citizen of Lenzburg (Switzerland), residing in Oberwil BL (Switzerland), and Mister Dr. Frank Sauer, German citizen, residing in Lörrach (Germany), both duly entitled to sign documents wherein property of the company is alienated.

Signers and signatures personally known to the Notary.

B a s e l (Switzerland), this 18th (eighteenth) day of July 2023 (two thousand and twenty-three).



BL 757 / 2023

01 JUN 23